cells Review Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment Katarzyna Piekarowicz † , Magdalena Machowska † , Volha Dzianisava and Ryszard Rzepecki * Laboratory of Nuclear Proteins, Faculty of Biotechnology, University of Wroclaw, Fryderyka Joliot-Curie 14a, 50-383 Wroclaw, Poland;
[email protected] (K.P.);
[email protected] (M.M.);
[email protected] (V.D.) * Correspondence:
[email protected]; Tel.: +48-71-3756308 † Joint first author. Received: 1 December 2018; Accepted: 19 January 2019; Published: 25 January 2019 Abstract: Hutchinson-Gilford progeria syndrome (HGPS) is one of the most severe disorders among laminopathies—a heterogeneous group of genetic diseases with a molecular background based on mutations in the LMNA gene and genes coding for interacting proteins. HGPS is characterized by the presence of aging-associated symptoms, including lack of subcutaneous fat, alopecia, swollen veins, growth retardation, age spots, joint contractures, osteoporosis, cardiovascular pathology, and death due to heart attacks and strokes in childhood. LMNA codes for two major, alternatively spliced transcripts, give rise to lamin A and lamin C proteins. Mutations in the LMNA gene alone, depending on the nature and location, may result in the expression of abnormal protein or loss of protein expression and cause at least 11 disease phenotypes, differing in severity and affected tissue. LMNA gene-related HGPS is caused by a single mutation in the LMNA gene in exon 11. The mutation c.1824C > T results in activation of the cryptic donor splice site, which leads to the synthesis of progerin protein lacking 50 amino acids.